Weinhoff Gregory M 4

What Happened

• Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals (CNTA), exercised 23,998 derivative awards at a strike of $3.85 (total exercise cost $92,392) and the same 23,998 shares were sold in the open market at $30.00 per share for total gross proceeds of $719,940 on March 26, 2026. The transactions were reported on Form 4 filed the same day.
• The filing also shows a derivative conversion/disposition line for 23,998 shares at $0.00; the Form 4 does not provide additional detail about that zero-dollar line.

Key Details

• Transaction date: 2026-03-26.
  • Option exercise (Code M — acquired): 23,998 shares @ $3.85 = $92,392.
  • Open-market sale (Code S — disposed): 23,998 shares @ $30.00 = $719,940.
  • Separate derivative disposition (Code M) for 23,998 shares reported at $0.00 (no consideration shown).
• Shares owned after the reported transactions: not specified in this filing.
• Footnotes:
  • F1: Ordinary Shares may be represented by American Depositary Shares (each currently = 1 Ordinary Share).
  • F2: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted Nov 12, 2025.
  • F3: The option vesting schedule is 1/48th per month beginning Mar 1, 2023.
• Filing timeliness: Reported and filed on 2026-03-26 (no late filing indicated).

Context

• Because the shares were exercised and sold the same day, this functions like a cashless exercise where the insider realizes the difference between the market price and the exercise price. Rough approximation of net proceeds before taxes/fees: $719,940 (sale) − $92,392 (exercise cost) ≈ $627,548.
• The sale was made under a pre-established Rule 10b5-1 plan, which typically indicates a pre-planned, formula-driven disposition rather than an ad-hoc trade.